$4.855
Live
Insights on Puma Biotechnology, Inc.
Revenue is up for the last 4 quarters, 52.77M → 72.17M (in $), with an average increase of 9.4% per quarter
Netprofit is up for the last 5 quarters, -5.6M → 12.26M (in $), with an average increase of 162.5% per quarter
In the last 3 years, Novo Nordisk A/s has given 247.4% return, outperforming this stock by 297.0%
0.41%
Downside
Day's Volatility :5.65%
Upside
5.26%
56.17%
Downside
52 Weeks Volatility :72.45%
Upside
37.13%
Period | Puma Biotechnology, Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 2.6% | 1.9% | 0.0% |
6 Months | 129.02% | 10.7% | 0.0% |
1 Year | 84.53% | 4.6% | -1.1% |
3 Years | -50.58% | 14.2% | -22.1% |
Market Capitalization | 249.2M |
Book Value | $1.12 |
Earnings Per Share (EPS) | 0.45 |
PE Ratio | 11.49 |
PEG Ratio | 0.03 |
Wall Street Target Price | 4.33 |
Profit Margin | 9.16% |
Operating Margin TTM | 21.37% |
Return On Assets TTM | 9.19% |
Return On Equity TTM | 57.54% |
Revenue TTM | 235.6M |
Revenue Per Share TTM | 5.0 |
Quarterly Revenue Growth YOY | 9.9% |
Gross Profit TTM | 172.9M |
EBITDA | 44.8M |
Diluted Eps TTM | 0.45 |
Quarterly Earnings Growth YOY | -0.78 |
EPS Estimate Current Year | 0.26 |
EPS Estimate Next Year | 0.17 |
EPS Estimate Current Quarter | 0.3 |
EPS Estimate Next Quarter | 0.0 |
What analysts predicted
Downside of 10.81%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 251.0M | ↑ 806.14% |
Net Income | -113.6M | ↓ 61.1% |
Net Profit Margin | -45.26% | ↑ 1008.89% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 272.3M | ↑ 8.49% |
Net Income | -82.7M | ↓ 27.18% |
Net Profit Margin | -30.38% | ↑ 14.88% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 225.1M | ↓ 17.33% |
Net Income | -60.0M | ↓ 27.47% |
Net Profit Margin | -26.65% | ↑ 3.73% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 253.2M | ↑ 12.48% |
Net Income | -29.1M | ↓ 51.5% |
Net Profit Margin | -11.49% | ↑ 15.16% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 228.0M | ↓ 9.95% |
Net Income | 912.0K | ↓ 103.13% |
Net Profit Margin | 0.4% | ↑ 11.89% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 235.6M | ↑ 3.35% |
Net Income | 21.6M | ↑ 2267.43% |
Net Profit Margin | 9.16% | ↑ 8.76% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 57.1M | ↓ 4.06% |
Net Income | -360.0K | ↓ 103.84% |
Net Profit Margin | -0.63% | ↓ 16.37% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 65.7M | ↑ 15.06% |
Net Income | -5.6M | ↑ 1455.56% |
Net Profit Margin | -8.52% | ↓ 7.89% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 52.8M | ↓ 19.67% |
Net Income | 1.4M | ↓ 125.02% |
Net Profit Margin | 2.65% | ↑ 11.17% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 54.6M | ↑ 3.4% |
Net Income | 2.1M | ↑ 51.75% |
Net Profit Margin | 3.9% | ↑ 1.25% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 56.1M | ↑ 2.84% |
Net Income | 5.8M | ↑ 172.62% |
Net Profit Margin | 10.33% | ↑ 6.43% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 72.2M | ↑ 28.62% |
Net Income | 12.3M | ↑ 111.66% |
Net Profit Margin | 17.0% | ↑ 6.67% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 259.1M | ↑ 56.55% |
Total Liabilities | 224.8M | ↑ 100.33% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 234.9M | ↓ 9.35% |
Total Liabilities | 217.4M | ↓ 3.28% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 244.2M | ↑ 3.97% |
Total Liabilities | 250.2M | ↑ 15.05% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 226.6M | ↓ 7.22% |
Total Liabilities | 229.0M | ↓ 8.45% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 222.1M | ↓ 2.0% |
Total Liabilities | 200.5M | ↓ 12.48% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 230.5M | ↑ 3.81% |
Total Liabilities | 177.1M | ↓ 11.66% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 198.8M | ↑ 2.64% |
Total Liabilities | 176.6M | ↑ 1.55% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 222.1M | ↑ 11.72% |
Total Liabilities | 200.5M | ↑ 13.5% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 196.3M | ↓ 11.62% |
Total Liabilities | 170.4M | ↓ 14.99% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 200.5M | ↑ 2.16% |
Total Liabilities | 170.1M | ↓ 0.18% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 203.6M | ↑ 1.55% |
Total Liabilities | 164.9M | ↓ 3.08% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 230.5M | ↑ 13.22% |
Total Liabilities | 177.1M | ↑ 7.41% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -24.1M | ↓ 86.03% |
Investing Cash Flow | -57.6M | ↑ 273.3% |
Financing Cash Flow | 108.4M | ↑ 44.34% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 22.4M | ↓ 192.95% |
Investing Cash Flow | 5.2M | ↓ 108.96% |
Financing Cash Flow | -67.1M | ↓ 161.9% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 800.0K | ↓ 96.43% |
Investing Cash Flow | 23.4M | ↑ 353.28% |
Financing Cash Flow | 100.0K | ↓ 100.15% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 20.7M | ↑ 2487.5% |
Investing Cash Flow | -10.9M | ↓ 146.49% |
Financing Cash Flow | -31.9M | ↓ 32000.0% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -15.8M | ↓ 176.33% |
Investing Cash Flow | 7.1M | ↓ 165.29% |
Financing Cash Flow | 12.2M | ↓ 138.24% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 17.3M | ↓ 224.4% |
Investing Cash Flow | 8.0M | ↑ 300.5% |
Financing Cash Flow | -53.0K | ↑ 17.78% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 7.7M | ↓ 55.48% |
Investing Cash Flow | -11.9M | ↓ 248.45% |
Financing Cash Flow | 2.4M | ↓ 4686.79% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 2.6M | ↓ 65.6% |
Investing Cash Flow | -17.5M | ↑ 46.97% |
Financing Cash Flow | 0.0 | ↓ 100.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 3.3M | ↑ 24.71% |
Investing Cash Flow | -4.7M | ↓ 73.16% |
Financing Cash Flow | 0.0 | - |
Sell
Neutral
Buy
Puma Biotechnology, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Puma Biotechnology, Inc. | -8.23% | 129.02% | 84.53% | -50.58% | -84.94% |
Moderna, Inc. | -2.26% | 35.27% | -21.9% | -39.25% | 318.83% |
Regeneron Pharmaceuticals, Inc. | -5.59% | 12.81% | 13.84% | 81.04% | 166.5% |
Novo Nordisk A/s | -0.32% | 31.91% | 50.92% | 247.21% | 431.9% |
Vertex Pharmaceuticals Incorporated | -2.67% | 9.62% | 21.65% | 86.62% | 134.62% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Puma Biotechnology, Inc. | 11.49 | 11.49 | 0.03 | 0.26 | 0.58 | 0.09 | NA | 1.12 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.9 | 25.9 | 1.46 | 45.02 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 47.09 | 47.09 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.81 | 28.81 | 0.53 | 16.76 | 0.23 | 0.13 | NA | 68.22 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Puma Biotechnology, Inc. | Sell | $249.2M | -84.94% | 11.49 | 9.16% |
Moderna, Inc. | Buy | $40.0B | 318.83% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.8B | 166.5% | 25.9 | 30.14% |
Novo Nordisk A/s | Buy | $558.9B | 431.9% | 47.09 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $103.4B | 134.62% | 28.81 | 36.68% |
Vanguard Group Inc
Millennium Management LLC
Camber Capital Management LLC
Acadian Asset Management LLC
Athyrium Capital Management LP
Eversept Partners, LLC
we focus on in-licensing innovative drug candidates that are undergoing or have already completed initial clinical testing for the treatment of various forms of cancer and then seek to further develop these drug candidates for commercial use.
Organization | Puma Biotechnology, Inc. |
Employees | 185 |
CEO | Mr. Alan H. Auerbach |
Industry | Health Technology |